ClinicalTrials.gg
Not yet recruitingNCT07697001Updated Jul 16, 2026

Clinical and Neurocomputational Effects of Behavioral Activation in Veterans With Impaired Social Functioning

An interventional study of Behavioral Activation (BA) and Supportive Care Therapy (SCT) in Social Anhedonia and Social Function Impairment, sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Anhedonia with a site in United States — 24 open to participants now, 25 under way, none of them phase 3. Anhedonia · United States.

Planned enrollment
11th of 67
136 · median 70
Started
2027
with 2 others
No phase
42 of 76
19 open now
Primary completion
2030-12
later than 22 of 24 live
Registered
74th of 76
by date

Among the 76 studies in Anhedonia with a site in United States, this one is the 11th largest by planned enrollment of the 67 interventional ones that give a count, is one of 3 that started in 2027, is one of 42 with no phase, reaches primary completion later than 22 of the 24 other live ones, and was the 74th registered.

Anhedonia

134 studies on the registry are indexed under Anhedonia; 50 are open to participants now.

Browse Anhedonia studies →

Open to participants now

24 of the 76 studies in Anhedonia with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Anhedonia studies recruiting now, 8 (19%) set no upper age limit and 33 (77%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Anhedonia with a site in United States, or all of them as a file.
02

Study summary

Poor psychosocial functioning, including social disconnection, is common and disabling among Veterans, and often fails to improve following the best available evidence-based treatments, particularly if more severe pathology is present. Behavioral activation (BA) is a promising, low-burden intervention, which could help improve social functioning impairments in Veterans, as this treatment targets social reward sensitivity, an important driving mechanism of social functioning. Thus, the proposed research will test whether BA can specifically improve social functioning in Veterans. Leveraging a neurocomputational framework of social reward seeking behavior, this research will help to improve the treatment and assessment of social function and the prediction of psychosocial treatment needs in Veterans, while providing neurobehavioral targets to develop new interventions that can restore social functioning.

Read the detailed description

Perceived social disconnection and social isolation are disabling and common among Veterans. Yet, these psychosocial impairments can fail to improve following the best available evidence-based treatments. Behavioral activation (BA), an evidence-based treatment for depression has shown promise in improving social functioning. However, most of this research was conducted in primarily non-Veteran populations and has typically relied on patients' subjective symptoms and self-report, in contrast to objective behavioral probes, to assess social functioning. Moreover, the cognitive mechanisms promoting social behavior remain poorly understood, particularly in Veterans. For instance, social anhedonia, i.e., a reduced sensitivity to social rewards, such as positive human interactions, has been implicated as an important driving mechanism of poor social functioning. Yet, the degree to which BA successfully target social reward sensitivity remains unclear and has not been evaluated in Veterans. This lack of understanding limits the ability to develop more targeted and effective interventions for psychosocial recovery. To address these gaps, this study aims to test the clinical and neurobehavioral effectiveness of BA in targeting social dysfunction in Veterans.

Computational models of reward learning (RL), particularly Bayesian RL learning models, can offer an important bridge to link in-vivo behavior, such as social reward sensitivity, and recovery outcomes like psychosocial functioning, by providing a rich quantitative representation of reward learning and its dynamic updating during reward exploration. This proposal aims to capitalize on this approach, combining a translational behavioral paradigm, Bayesian reinforcement learning modeling, and neuroscientific evaluation of change processes, in order to assay social anhedonia and improve prediction of social functioning as well as understanding and effective dissemination of BA treatment.

The specific aims are to: 1) test the effectiveness of BA in improving social functioning outcomes in Veterans (Aim 1); 2) examine the impact of BA on neurocomputational markers of social reward sensitivity and their relationship to social functioning improvement in Veterans (Aim 2); and 3) assess the degree to which neurocomputational markers of social reward sensitivity predict social functioning recovery in Veterans undergoing BA (Aim 3). This project will also explore whether the relationships between neurocomputational markers of social function and clinical outcomes are moderated by primary diagnosis (exploratory Aim 4).

Veterans (N=136) with impaired social functioning and anhedonia will be recruited and randomized to either behavioral activation (BA) or supportive care therapy (SCT; active control) over 12 weeks. At baseline, immediately post-treatment, and 12-weeks post-treatment (24-weeks follow-up), participants will complete a computerized task aimed at probing social reward-seeking behavior, in which they must choose between unknown partners with the goal of maximizing the number of compliments they receive from these partners. Concurrent brain activity will be collected with functional magnetic resonance imaging (fMRI) in a subset of participants (N=68; at baseline and post-treatment). Therapy sessions and follow-up (24-weeks) assessments will be administered through VA-approved telehealth methods. Computational modeling will be used to derive individual parameters of social reward (i.e., compliments) learning and maximization, and to extract associated neural activity, e.g., neural responses to prediction error signals (discrepancies between expected and actually obtained reward/compliment). Randomization of participants to treatment arms will be be stratified based on fMRI eligibility status, sex, and primary psychiatric diagnosis.

This project is expected to 1) determine if BA offers an effective, low-burden option to improve social functioning in Veterans; 2) identify potential neurocognitive targets, which could be used in future research to develop and test novel treatments to improve psychosocial functioning in Veterans, such as computerized neurocomputational training protocols to boost social reward sensitivity; and 3) help identify precise markers of BA responsiveness for functional recovery.

03

Conditions studied

  • Social Anhedonia
  • Social Function Impairment

Keywords

  • Social Functioning
  • Social Reward
  • Anhedonia
  • Reinforcement Learning
  • Magnetic Resonance Imaging
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • being a Veteran
  • having moderate to high levels of social disconnection (Social Connectedness Scale-Revised/SCS-R score \< 90)
  • having moderate to high levels of social functioning impairments (Sheehan Disability Scale/SDS-social domain score >=5)
  • having moderate to high levels of social anhedonia (Specific Loss of Interest and Pleasure Scale/SLIPS score >= 6)

Exclusion criteria

Exclusion Criteria:

  • lifetime history of psychotic or bipolar disorder
  • neurological conditions, neurodevelopmental disorders, or sensory deficits that may impact cognitive functioning to preclude understanding/completion of study procedure
  • regular use of certain psychotropic medications that may significantly impact goal-directed performance on the task (i.e., benzodiazepines, sedative hypnotics, and opioid analgesics); pre-existing stable doses of psychotropic medications, such as SSRIs, will be allowed (if same regimen has been taken for at least 30 days)
  • current severe alcohol or substance use disorders (AUD/SUD) necessitating prioritization of substance use treatment
  • suicidal or homicidal ideation within the past month necessitating urgent higher-level care
  • concurrent individual cognitive-behavioral psychotherapy specifically targeting depression, anhedonia, and/or PTSD
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
136 participants (estimated)

Study arms

  • Experimental
    Behavioral Activation (BA)

    This arm provides the experimental treatment, i.e., Behavioral Activation therapy.

    Behavioral: Behavioral Activation (BA)

  • Active comparator
    Supportive Care Therapy (SCT)

    This arm provides the active control treatment, i.e., Supportive Care Therapy.

    Behavioral: Supportive Care Therapy (SCT)

Interventions

  • BehavioralBehavioral Activation (BA)

    BA is a structured behavioral protocol for depression, designed to help individuals increase engagement in meaningful and rewarding activities, thereby breaking the cycle of avoidance and inactivity that often accompanies depression. The protocol teaches patients to increase a) engagement in pleasant, reinforcing activities, with a strong emphasis on social engagement and social connection, b) exploration of values, and c) goal-setting and goal-directed behavior, while monitoring their mood and daily activities

  • BehavioralSupportive Care Therapy (SCT)

    SCT is a Rogerian non-directive approach and employs techniques to convey a deep understanding of emotions, thoughts, and behaviors of the Veterans receiving this treatment. Specific techniques include content-focused paraphrasing, exploration through open-ended questions (with a goal of empathic understanding), and emotion-focused reflection and validation. Consistent with the SCT model, the therapist will be explicitly instructed not to provide advice, assign activities, or suggest strategies and techniques employed in the BA intervention.

06

What researchers measure

Primary outcomes

  1. Social Connectedness Scale - Revised (SCS-R)

    Measures the degree to which individuals feel connected to others in their social environment. Scores range from 20 to 120, where higher scores indicate a stronger, healthier sense of social connectedness.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  2. Inventory of Psychosocial Functioning (IPF)

    The scale measures the degree of impairment in ability to interact effectively with others, fulfill social roles (e.g., work), and meet personal and societal expectations. It is comprised of 7 subscales. Each item ranges from 0 to 6. Higher scores indicate greater degree of impairment in psychosocial functioning.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  3. Specific Loss of Interest and Pleasure Scale (SLIPS)

    This is a measure of social anhedonia, i.e., hypo-responsiveness to social rewards, such as positive human interactions. Scores range from 0 to 69. Higher scores indicate greater severity of social anhedonia.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  4. Social Reward Maximization

    Computational parameter derived from behavioral social functioning probe (behavioral reinforcement learning task), capturing the degree to which individuals select social partners they predict to be more rewarding (to offer the most compliments).

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  5. Neural Activation to Social Reward Prediction Errors (RPEs)

    Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with individuals' model-based RPE (difference between expected probability of reward/compliment and actual outcome received. i.e., compliment vs no-compliment).

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

Secondary outcomes

  1. Primary Psychiatric Diagnosis

    Primary diagnostic category (i.e., depressive vs traumatic stress/anxiety disorder)

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  2. World Health Organization Quality of Life Scale (WHOQOL-BREF)

    Measures quality of life and life satisfaction. Includes 4 domain subscales: physical health (range 7-35), psychological health (range 6-30), social relationships (range 3-15), and environment (range 8-42). Higher scores indicate higher quality of life.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  3. Patient Health Questionnaire-9 (PHQ-9)

    Measures depression severity. Scores range from 0 to 27. Higher scores indicate greater depression severity.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  4. PTSD Checklist-5 (PCL-5)

    Measures post-traumatic stress disorder (PTSD) severity. Scores range from 0 to 80, with higher scores indicating greater PTSD severity.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  5. Beck Anxiety Inventory (BAI)

    This scale measures anxiety severity. Scores range from 0 to 63, with higher scores indicating greater anxiety severity.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  6. Snaith-Hamilton Pleasure Scale (SHAPS)

    Measure of anhedonia. Score range from 14 to 56, with higher scores indicating greater anhedonia severity.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

Other outcomes

  1. Reaction to Treatment Questionnaire

    Measure of treatment satisfaction and credibility of treatment rationale. Total scores range from 3 to 27, with higher scores indicating greater satisfaction and credibility in the treatment.

    Time frame: Baseline, Post-Treatment (12-weeks)

  2. Mood and Anxiety Symptoms Questionnaire (MASQ-D30)

    Measure of anhedonic depression, anxiety, and stress symptoms. The scale has three subscales (general distress, anhedonic depression, and anxious arousal) , with each score ranging from 10 to 50. Higher scores indicate greater severity of symptoms.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

  3. Liebowitz Social Anxiety Scale (LSAS)

    Assesses the impact of social anxiety on multiple aspects of life. Scores range from 0 to 144, with higher scores indicating greater social anxiety.

    Time frame: Baseline, Post-Treatment (12 weeks), Follow-Up (24 weeks)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — One or more data sets without personal identifiers will be generated during the data analysis phase of this study. The data sets will include all data underlying any publications generated by this study as well as statistical code, and therefore these will be sufficient to reproduce or verify any published findings. Any HIPAA identifiers, or combinations of variables that could be used for re-identification, will be excluded, as will any proprietary information. The plan does not include any access to individually identifiable or proprietary data. Therefore, this plan will ensure the protection of personal privacy, the confidentiality of individually identifiable private information, and the security of proprietary data and information.

Supporting information: Analytic code

Time frame: IPD and supporting information will become available upon completion of the study and publication of the the results.

Access criteria: Final de-identified datasets in machine-readable format will be submitted to and accessed from PubMed Central (and similar sites); care will be taken to ensure that individuals cannot be re-identified using other publicly available information.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2030, 47 months later.

Of 58 non-industry interventional studies with no phase under Anhedonia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 46. This study's planned 47 months is above that.

Counting every sponsor, half of 65 studies reached it within 26 months; a quarter within 14 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2026
First posted
Jul 10, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07697001
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jul 16, 2026

Study contacts

Katia Harle, MD
Contact
Katia.Harle@va.gov
(858) 642-3657
Katia Harle, MD
principal investigator · VA San Diego Healthcare System, San Diego, CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion